HUP0202714A2 - Radiopharmaceutical products and their preparation procedure - Google Patents

Radiopharmaceutical products and their preparation procedure Download PDF

Info

Publication number: HUP0202714A2
Authority: HU; Hungary
Prior art keywords: polysaccharide; group; radiotherapy; product according; complexing groups
Prior art date: 1999-09-01

Application number

HU0202714A

Other languages

English (en)

Hungarian (hu)

Inventor

Bellande

Denizot

Jallet

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-01

Filing date

2000-08-23

Publication date

2002-12-28

2000-08-23 Application filed by Schering Ag filed Critical Schering Ag

2002-12-28 Publication of HUP0202714A2 publication Critical patent/HUP0202714A2/hu

Links

238000000034 method Methods 0.000 title claims abstract description 31
238000002360 preparation method Methods 0.000 title claims description 7
239000012217 radiopharmaceutical Substances 0.000 title description 3
229940121896 radiopharmaceutical Drugs 0.000 title description 3
230000002799 radiopharmaceutical effect Effects 0.000 title description 3
229920001282 polysaccharide Polymers 0.000 claims abstract description 48
239000005017 polysaccharide Substances 0.000 claims abstract description 48
150000004676 glycans Chemical class 0.000 claims abstract description 46
238000001959 radiotherapy Methods 0.000 claims abstract description 35
229920002472 Starch Polymers 0.000 claims abstract description 30
239000008107 starch Substances 0.000 claims abstract description 30
235000019698 starch Nutrition 0.000 claims abstract description 29
230000000536 complexating effect Effects 0.000 claims abstract description 24
239000011859 microparticle Substances 0.000 claims abstract description 21
230000002285 radioactive effect Effects 0.000 claims abstract description 20
229910052717 sulfur Inorganic materials 0.000 claims abstract description 17
229920002678 cellulose Polymers 0.000 claims abstract description 16
239000001913 cellulose Substances 0.000 claims abstract description 15
229910052751 metal Inorganic materials 0.000 claims abstract description 15
239000002184 metal Substances 0.000 claims abstract description 15
229920000945 Amylopectin Polymers 0.000 claims abstract description 14
125000003118 aryl group Chemical group 0.000 claims abstract description 14
229910052713 technetium Inorganic materials 0.000 claims abstract description 12
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims abstract description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
238000009549 lung scintigraphy Methods 0.000 claims abstract description 9
230000008569 process Effects 0.000 claims abstract description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
125000004434 sulfur atom Chemical group 0.000 claims abstract description 7
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 6
229910052802 copper Inorganic materials 0.000 claims abstract description 6
239000010949 copper Substances 0.000 claims abstract description 6
238000004519 manufacturing process Methods 0.000 claims abstract description 6
229910052702 rhenium Inorganic materials 0.000 claims abstract description 6
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims abstract description 6
239000004215 Carbon black (E152) Substances 0.000 claims abstract description 5
229910052691 Erbium Inorganic materials 0.000 claims abstract description 5
229910052772 Samarium Inorganic materials 0.000 claims abstract description 5
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims abstract description 5
229930195733 hydrocarbon Natural products 0.000 claims abstract description 5
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052727 yttrium Inorganic materials 0.000 claims abstract description 5
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims abstract description 5
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims abstract description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
229910052733 gallium Inorganic materials 0.000 claims abstract description 3
125000005842 heteroatom Chemical group 0.000 claims abstract description 3
125000001424 substituent group Chemical group 0.000 claims abstract description 3
229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract description 3
125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 6
239000013522 chelant Substances 0.000 claims abstract 2
239000004005 microsphere Substances 0.000 claims description 39
239000000725 suspension Substances 0.000 claims description 26
238000007254 oxidation reaction Methods 0.000 claims description 18
230000003647 oxidation Effects 0.000 claims description 15
150000001875 compounds Chemical class 0.000 claims description 10
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 8
235000011150 stannous chloride Nutrition 0.000 claims description 8
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 7
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 claims description 6
WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 4
239000012279 sodium borohydride Substances 0.000 claims description 4
229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
-1 R-NH- Chemical class 0.000 claims description 3
238000009007 Diagnostic Kit Methods 0.000 claims description 2
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims description 2
RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims description 2
UYAHIZSMUZPPFV-NJFSPNSNSA-N erbium-169 Chemical compound [169Er] UYAHIZSMUZPPFV-NJFSPNSNSA-N 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
239000003814 drug Substances 0.000 claims 1
238000003745 diagnosis Methods 0.000 abstract description 4
GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 abstract description 2
238000002560 therapeutic procedure Methods 0.000 abstract description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
239000000243 solution Substances 0.000 description 28
239000000047 product Substances 0.000 description 26
238000002372 labelling Methods 0.000 description 24
229920000881 Modified starch Polymers 0.000 description 23
239000004368 Modified starch Substances 0.000 description 23
235000019426 modified starch Nutrition 0.000 description 23
238000005859 coupling reaction Methods 0.000 description 22
239000001254 oxidized starch Substances 0.000 description 22
235000013808 oxidized starch Nutrition 0.000 description 22
210000004072 lung Anatomy 0.000 description 21
230000008878 coupling Effects 0.000 description 20
238000010168 coupling process Methods 0.000 description 20
239000002245 particle Substances 0.000 description 19
235000010980 cellulose Nutrition 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000000203 mixture Substances 0.000 description 13
230000004048 modification Effects 0.000 description 12
238000012986 modification Methods 0.000 description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
150000001299 aldehydes Chemical group 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000008103 glucose Substances 0.000 description 11
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
238000000921 elemental analysis Methods 0.000 description 10
239000000843 powder Substances 0.000 description 10
239000011593 sulfur Substances 0.000 description 10
102000008100 Human Serum Albumin Human genes 0.000 description 8
108091006905 Human Serum Albumin Proteins 0.000 description 8
125000003876 thiosemicarbazone group Chemical group 0.000 description 8
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
239000002262 Schiff base Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000000052 comparative effect Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
150000004753 Schiff bases Chemical class 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
BRWIZMBXBAOCCF-UHFFFAOYSA-N thiosemicarbazide group Chemical group NNC(=S)N BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 4
VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
230000029142 excretion Effects 0.000 description 3
230000005251 gamma ray Effects 0.000 description 3
230000036512 infertility Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000005303 weighing Methods 0.000 description 3
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
LLCOQBODWBFTDD-UHFFFAOYSA-N 1h-triazol-1-ium-4-thiolate Chemical group SC1=CNN=N1 LLCOQBODWBFTDD-UHFFFAOYSA-N 0.000 description 2
XDSDZQGMWPHUJZ-UHFFFAOYSA-N 2-amino-1h-triazole-5-thione Chemical compound NN1N=CC(=S)N1 XDSDZQGMWPHUJZ-UHFFFAOYSA-N 0.000 description 2
KKIGUVBJOHCXSP-UHFFFAOYSA-N 4-phenylthiosemicarbazide Chemical compound NNC(=S)NC1=CC=CC=C1 KKIGUVBJOHCXSP-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
ZXVCKEPDGHZEMR-UHFFFAOYSA-N CN(C([SH2]C)=S)N Chemical compound CN(C([SH2]C)=S)N ZXVCKEPDGHZEMR-UHFFFAOYSA-N 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000008139 complexing agent Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229930182478 glucoside Natural products 0.000 description 2
150000008131 glucosides Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
ILAXBOIRSPXAMM-UHFFFAOYSA-N methyl n-aminocarbamodithioate Chemical compound CSC(=S)NN ILAXBOIRSPXAMM-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000005164 penile vein Anatomy 0.000 description 2
150000003141 primary amines Chemical group 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000001119 stannous chloride Substances 0.000 description 2
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 2
150000003584 thiosemicarbazones Chemical class 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
BZQAWHMCGZYKMH-UHFFFAOYSA-N 2-aminoethanethiol Chemical compound NCCS.NCCS BZQAWHMCGZYKMH-UHFFFAOYSA-N 0.000 description 1
FCPHVJQWZFNNKD-UHFFFAOYSA-N 3-amino-1,1-dimethylthiourea Chemical compound CN(C)C(=S)NN FCPHVJQWZFNNKD-UHFFFAOYSA-N 0.000 description 1
PTVZQOAHCSKAAS-UHFFFAOYSA-N 4-methyl-3-thiosemicarbazide Chemical compound CNC(=S)NN PTVZQOAHCSKAAS-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000012615 aggregate Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229940006110 gallium-67 Drugs 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000002767 hepatic artery Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
108010013207 macro aggregates of albumin Proteins 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229960003151 mercaptamine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002331 radioactive microsphere Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000005005 sentinel lymph node Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HU0202714A 1999-09-01 2000-08-23 Radiopharmaceutical products and their preparation procedure HUP0202714A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9910970A FR2797769B1 (fr)	1999-09-01	1999-09-01	Produits radiopharmaceutiques et leur procede de preparation
PCT/IB2000/001161 WO2001015746A1 (en)	1999-09-01	2000-08-23	Radiopharmaceutical products and their preparation procedure

Publications (1)

Publication Number	Publication Date
HUP0202714A2 true HUP0202714A2 (en)	2002-12-28

Family

ID=9549465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0202714A HUP0202714A2 (en)	1999-09-01	2000-08-23	Radiopharmaceutical products and their preparation procedure

Country Status (23)

Country	Link
EP (1)	EP1210127A1 (pl)
JP (1)	JP2003508455A (pl)
KR (1)	KR20020040799A (pl)
CN (1)	CN1371292A (pl)
AU (1)	AU6463100A (pl)
BG (1)	BG106438A (pl)
BR (1)	BR0013729A (pl)
CA (1)	CA2383517A1 (pl)
CZ (1)	CZ2002782A3 (pl)
EA (1)	EA200200307A1 (pl)
EE (1)	EE200200105A (pl)
FR (1)	FR2797769B1 (pl)
HK (1)	HK1044893A1 (pl)
HU (1)	HUP0202714A2 (pl)
IL (1)	IL148076A0 (pl)
MX (1)	MXPA02001923A (pl)
NO (1)	NO20021001L (pl)
NZ (1)	NZ517377A (pl)
PL (1)	PL353803A1 (pl)
SK (1)	SK2772002A3 (pl)
WO (1)	WO2001015746A1 (pl)
YU (1)	YU14202A (pl)
ZA (1)	ZA200201057B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094369B2 (en)	2002-03-29	2006-08-22	Scimed Life Systems, Inc.	Processes for manufacturing polymeric microspheres
US7131997B2 (en)	2002-03-29	2006-11-07	Scimed Life Systems, Inc.	Tissue treatment
US7462366B2 (en)	2002-03-29	2008-12-09	Boston Scientific Scimed, Inc.	Drug delivery particle
US7053134B2 (en)	2002-04-04	2006-05-30	Scimed Life Systems, Inc.	Forming a chemically cross-linked particle of a desired shape and diameter
US7842377B2 (en)	2003-08-08	2010-11-30	Boston Scientific Scimed, Inc.	Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en)	2002-08-09	2008-11-11	Boston Scientific Scimed, Inc.	Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en)	2002-08-30	2011-09-06	Boston Scientific Scimed, Inc.	Embolization
US7588825B2 (en)	2002-10-23	2009-09-15	Boston Scientific Scimed, Inc.	Embolic compositions
US7883490B2 (en)	2002-10-23	2011-02-08	Boston Scientific Scimed, Inc.	Mixing and delivery of therapeutic compositions
US7976823B2 (en)	2003-08-29	2011-07-12	Boston Scientific Scimed, Inc.	Ferromagnetic particles and methods
US7901770B2 (en)	2003-11-04	2011-03-08	Boston Scientific Scimed, Inc.	Embolic compositions
US7736671B2 (en)	2004-03-02	2010-06-15	Boston Scientific Scimed, Inc.	Embolization
US8173176B2 (en)	2004-03-30	2012-05-08	Boston Scientific Scimed, Inc.	Embolization
US7311861B2 (en)	2004-06-01	2007-12-25	Boston Scientific Scimed, Inc.	Embolization
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US7727555B2 (en)	2005-03-02	2010-06-01	Boston Scientific Scimed, Inc.	Particles
US7858183B2 (en)	2005-03-02	2010-12-28	Boston Scientific Scimed, Inc.	Particles
US7963287B2 (en)	2005-04-28	2011-06-21	Boston Scientific Scimed, Inc.	Tissue-treatment methods
US9463426B2 (en)	2005-06-24	2016-10-11	Boston Scientific Scimed, Inc.	Methods and systems for coating particles
US7947368B2 (en)	2005-12-21	2011-05-24	Boston Scientific Scimed, Inc.	Block copolymer particles
US7501179B2 (en)	2005-12-21	2009-03-10	Boston Scientific Scimed, Inc.	Block copolymer particles
FR2919189A1 (fr) *	2007-07-26	2009-01-30	Cyclopharma Sa Lab	Nouvelles compositions a base de polyosides greffes par des composes polyamines ou polysoufres.
CN102977174B (zh) *	2012-12-19	2015-04-22	北京师范大学	99mTc(CO)3核标记大环多胺三唑环类葡萄糖基配合物及制备方法和应用
PL240772B1 (pl)	2018-06-11	2022-06-06	Nanothea Spolka Akcyjna	Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7412164L (sv) *	1974-09-27	1976-03-29	Pharmacia Ab	Medel for intravaskuler administrering
US5672334A (en) *	1991-01-16	1997-09-30	Access Pharmaceuticals, Inc.	Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
DE69332952T2 (de) *	1992-09-04	2004-02-19	The General Hospital Corp., Boston	Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5958372A (en) *	1994-06-28	1999-09-28	Nycomed Imaging As	Low viscosity chelating polymers for diagnostic imaging
FR2736834B1 (fr) *	1995-07-17	1997-08-29	Cis Bio Int	Produits radiopharmaceutiques a tropisme cardiaque comportant un complexe nitruro d'un metal de transition et ayant une clairance myocardique rapide

1999
- 1999-09-01 FR FR9910970A patent/FR2797769B1/fr not_active Expired - Fee Related
2000
- 2000-08-23 EA EA200200307A patent/EA200200307A1/ru unknown
- 2000-08-23 NZ NZ517377A patent/NZ517377A/en unknown
- 2000-08-23 CZ CZ2002782A patent/CZ2002782A3/cs unknown
- 2000-08-23 PL PL00353803A patent/PL353803A1/pl unknown
- 2000-08-23 KR KR1020027002820A patent/KR20020040799A/ko not_active Withdrawn
- 2000-08-23 WO PCT/IB2000/001161 patent/WO2001015746A1/en not_active Ceased
- 2000-08-23 CA CA002383517A patent/CA2383517A1/en not_active Abandoned
- 2000-08-23 YU YU14202A patent/YU14202A/sh unknown
- 2000-08-23 AU AU64631/00A patent/AU6463100A/en not_active Abandoned
- 2000-08-23 IL IL14807600A patent/IL148076A0/xx unknown
- 2000-08-23 BR BR0013729-4A patent/BR0013729A/pt not_active IP Right Cessation
- 2000-08-23 EP EP00951784A patent/EP1210127A1/en not_active Withdrawn
- 2000-08-23 JP JP2001520157A patent/JP2003508455A/ja active Pending
- 2000-08-23 CN CN00812300A patent/CN1371292A/zh active Pending
- 2000-08-23 SK SK277-2002A patent/SK2772002A3/sk unknown
- 2000-08-23 EE EEP200200105A patent/EE200200105A/xx unknown
- 2000-08-23 HU HU0202714A patent/HUP0202714A2/hu unknown
- 2000-08-23 HK HK02106423.2A patent/HK1044893A1/zh unknown
- 2000-08-23 MX MXPA02001923A patent/MXPA02001923A/es not_active Application Discontinuation
2002
- 2002-02-06 ZA ZA200201057A patent/ZA200201057B/xx unknown
- 2002-02-26 BG BG06438A patent/BG106438A/bg unknown
- 2002-02-28 NO NO20021001A patent/NO20021001L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2001015746A1 (en)	2001-03-08
BG106438A (bg)	2002-09-30
CN1371292A (zh)	2002-09-25
FR2797769A1 (fr)	2001-03-02
ZA200201057B (en)	2003-07-30
HK1044893A1 (zh)	2002-11-08
YU14202A (sh)	2004-09-03
EA200200307A1 (ru)	2002-08-29
BR0013729A (pt)	2002-05-07
NZ517377A (en)	2003-08-29
PL353803A1 (pl)	2003-12-01
SK2772002A3 (en)	2002-09-10
EP1210127A1 (en)	2002-06-05
FR2797769B1 (fr)	2003-07-25
CA2383517A1 (en)	2001-03-08
MXPA02001923A (es)	2003-07-21
EE200200105A (et)	2003-04-15
NO20021001D0 (no)	2002-02-28
IL148076A0 (en)	2002-09-12
NO20021001L (no)	2002-04-11
JP2003508455A (ja)	2003-03-04
AU6463100A (en)	2001-03-26
CZ2002782A3 (cs)	2002-08-14
KR20020040799A (ko)	2002-05-30

Publication	Publication Date	Title
HUP0202714A2 (en)	2002-12-28	Radiopharmaceutical products and their preparation procedure
CN117159753A (zh)	2023-12-05	放射性标记的伊文思蓝衍生物药物的制备方法及用途
EP2471557A1 (en)	2012-07-04	A conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes
EP2175888B1 (en)	2012-06-13	Radiopharmaceutical compositions comprising polysaccharides grafted by polyamines
EP3711781A1 (en)	2020-09-23	Method for preparation of radioisotope chelating polymer nanoparticles for use in diagnostics and treatment
US4250161A (en)	1981-02-10	Method and kit for the preparation of radiopharmaceuticals
AU763988B2 (en)	2003-08-07	Kit for the preparation of technetium Tc99m teboroxime myocardial perfusion agent
WO2001070724A1 (en)	2001-09-27	Radioisotope-labeled complexes of glucose derivatives and kits for the preparation thereof
US7320784B1 (en)	2008-01-22	Immobilized labeling compounds and methods
JPS5842846B2 (ja)	1983-09-22	肝臓および骨髄走査用テクネチウム−９９ｍ標識放射線診断剤とその製造法
JPS63170400A (ja)	1988-07-14	放射性医薬品とその調製用高分子化合物
LI et al.	0	RADIOPHARMAZEUTISCHE ZUSAMMENSETZUNGEN DIE POLYAMINE GEPFROPFTE POLYSACCHARIDE ENTHALTEN COMPOSITIONS RADIOPHARMACEUTIQUES COMPRENANT DES POLYSACCHARIDES GREFFÉS AVEC DES POLYAMINES
JPH0615478B2 (ja)	1994-03-02	放射性医薬品とその調製用高分子化合物
KR20030081865A (ko)	2003-10-22	수소화붕소 교환수지를 이용한 테크네튬 또는 레늄의표지방법
JPH0759524B2 (ja)	1995-06-28	放射性医薬品とその調製用高分子化合物
HK1149211B (en)	2014-01-24	Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
CZ277786B6 (en)	1993-04-14	PROCESS FOR PREPARING RADIO DIAGNOSTIC MEANS WITH A COMPLEX 99m Tc-d,1-4,8-DIAZA-3,6,6,9-TETRAMETHYLUNDECANE-2,10-BISOXIME